JMP Securities Reiterates “Buy” Rating for Axovant Sciences (AXON)
Axovant Sciences (NASDAQ:AXON)‘s stock had its “buy” rating reiterated by stock analysts at JMP Securities in a research note issued to investors on Monday. They currently have a $6.00 price target on the biotechnology company’s stock. JMP Securities’ price objective points to a potential upside of 380.00% from the company’s previous close.
Other analysts have also recently issued research reports about the company. BidaskClub cut Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 8th. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research report on Monday, January 7th. Jefferies Financial Group upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Monday, December 17th. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research report on Sunday, November 11th. Finally, ValuEngine cut Axovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $4.25.
NASDAQ:AXON opened at $1.25 on Monday. The firm has a market cap of $152.85 million, a PE ratio of -0.61 and a beta of 1.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.02 and a quick ratio of 2.02. Axovant Sciences has a 52-week low of $0.93 and a 52-week high of $6.59.
In related news, major shareholder Svf Investments (Uk) Ltd acquired 10,000,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 18th. The stock was purchased at an average price of $1.00 per share, for a total transaction of $10,000,000.00. Following the transaction, the insider now owns 99,285,714 shares in the company, valued at approximately $99,285,714. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.00% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of AXON. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Axovant Sciences by 12.9% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock worth $1,354,000 after purchasing an additional 64,152 shares during the period. BlackRock Inc. grew its holdings in shares of Axovant Sciences by 13.5% during the 3rd quarter. BlackRock Inc. now owns 1,424,710 shares of the biotechnology company’s stock worth $3,447,000 after purchasing an additional 169,918 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in shares of Axovant Sciences by 60.5% during the 3rd quarter. Renaissance Technologies LLC now owns 2,091,700 shares of the biotechnology company’s stock worth $5,062,000 after purchasing an additional 788,100 shares during the period. Institutional investors own 7.58% of the company’s stock.
Axovant Sciences Company Profile
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
Further Reading: What is Liquidity?
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.